BillionaireNet
Duggan
Robert Duggan
Rank #250
UNITED STATESHealthcarePharmaceuticals

Robert Duggan

Net Worth
$11.62B
+0.13% (24h)
Robert Duggan is an 81-year-old American entrepreneur and investor who has built a $12.1 billion fortune primarily through the pharmaceuticals industry. His career spans over five decades, marked by a knack for identifying and nurturing promising ventures. Duggan is known for his role as CEO of Pharmacyclics, where he spearheaded the development of the cancer drug Imbruvica, and for his current position as Co-CEO of Summit Therapeutics. He has a strong commitment to philanthropy, particularly supporting the Church of Scientology, to which he has donated over $360 million.

The Full Dossier

Early Life

Robert W. Duggan was born in Oakland, California, in 1944. He grew up as the third of five children in a lower-middle-class household in San Jose, California. His father was an industrial engineer, and his mother was a nurse. Duggan attended St. Francis High School in Mountain View, California, where he was the football team captain. He later studied economics at the University of California, Santa Barbara, and business management at the University of California, Los Angeles, though he did not complete a degree.

Rise to Success

Duggan's entrepreneurial journey began in 1971 with investments in various startups. He experienced early success with businesses such as a cookie bakery and a craft company. In the late 1990s, he became CEO of Computer Motion, a company specializing in robotic surgical systems. His most significant achievement came with his investment and leadership at Pharmacyclics. He became the CEO of the company in 2008 and oversaw the development of Imbruvica, a breakthrough cancer drug. Under Duggan's leadership, Pharmacyclics was sold to AbbVie in 2015 for $21 billion.

Key Business Strategies

Duggan's key strategies revolve around identifying and investing in companies with high potential. He has a history of taking leadership roles in companies, as seen with Pharmacyclics and Summit Therapeutics. Duggan is known for his ability to turn around struggling companies. His investment approach often involves taking significant ownership and actively participating in the company's strategic direction.

Philanthropy

Duggan is actively involved in philanthropy and has donated to various organizations. He is a major donor to the Church of Scientology, with donations exceeding $360 million. Duggan has also supported educational endeavors, including athletic departments and faculty chair positions at the University of California, Santa Barbara.

Career Timeline

2020

Co-CEO of Summit Therapeutics

Invested in and became Co-CEO of Summit Therapeutics

2015

Pharmacyclics Sale

Pharmacyclics was acquired by AbbVie for $21 billion.

2008-2015

CEO of Pharmacyclics

Led the company as CEO, oversaw the development of Imbruvica.

1997-2003

CEO of Computer Motion, Inc.

Served as the CEO of a company specializing in robotic surgical systems.

1971

Startup Investor

Began his career as an investor and founder of startups.

Philanthropic Impact

Religious$360M+

Church of Scientology Donations

Major donor to the Church of Scientology

EducationUndisclosed

UCSB Support

Supports educational endeavors, including athletic departments and faculty chairs

General PhilanthropyVaries

Robert W Duggan Foundation

Grants to various non-profit organizations

Wealth Trajectory